healthcare

Novaremed AG, a Basel, Switzerland-based clinical-stage biopharmaceutical company, announced, signed an agreement with GEM Global Yield LLC SCS (GEM), a Luxembourg-based private, alternative investment group for a US $50m capital commitment.